Take Your Mission Beyond the Exam Room
The field of community oncology is always changing. In a constantly evolving landscape, we must keep our finger on the pulse so we can create meaningful change for patients. To truly drive change and take this mission beyond the exam room, we must empower everyone in our community to be a stronger advocate.
The Community Oncology Alliance’s (COA) 2025 Community Oncology Conference brings together every facet of independent community oncology with the shared goal of ensuring patients have continued access to high-quality cancer care in the communities where they live and work. Joining us will be 2,000+ leaders from across the industry, including physicians, practice administrators and leaders, pharmacists and pharmacy technicians, nurses and advanced practice providers, and industry stakeholders.
Aligning with the core mission of COA is this year’s Conference theme, Empower & Advocate: Independent Community Oncology.
Over two days of learning and networking, attendees will get to choose from industry leading plenary sessions, along with four unique tracks covering clinical, business, pharmacy, and advocacy topics uniquely targeted to the needs of independent practices.
Become an empowered advocate, gain the knowledge to succeed, and network with key decision makers from across the industry at the 2025 Community Oncology Conference on April 29 – 30 outside Orlando, Florida.
Who Should Attend?
We invite all community oncology physicians, pharmacists/pharmacy techs, nurses/advanced practice providers, practice administrators/leaders, hematology/oncology fellows, policy or patient advocates, and industry stakeholders who support us. The 2025 COA Conference has something for everyone!






Don’t Miss Out On EARLY BIRD Prices – Register TODAY!
Already decided to join us? Save 20% if you qualify and complete your registration by Monday, February 24, 2025. Visit Registration Pricing, under Attend in the menu for more information.







An Agenda for Cancer Care Thought Leaders
Independent community oncology practices across the country are providing patients with high-quality, evidence-based, and cutting-edge cancer care that is affordable and accessible. Yet, they face ongoing challenges.
How can practices stay competitive among ongoing consolidation? How and when should care teams integrate new cancer care advancements into care plans? How can community oncology practices and patients leverage their collective power to make a difference in policy discussions? Those questions and others will be tackled at the 2025 COA Conference.
Detailed information on the agenda will be available soon, so keep your eyes peeled!

ACPE Credits for Returning Oncology Pharmacists
Pharmacists who attend this year’s Conference can receive continuing education (CE) credits for certain sessions through the Accreditation Council for Pharmacy Education (ACPE). These credits can help you meet your CE requirements for the year and position you for success.
More information on specific credits and courses coming soon!


Co-Chairs
Each year, the Conference co-chairs select speakers that are on the frontlines of independent community oncology. They consider not only professional accolades but connections: Are they advocates? Do they uplift other practice professionals? Are they creating diverse coalitions to create change? For each speaker at the 2025 Community Oncology Conference, the answer is yes!
The 2025 Community Oncology Conference co-chairs are:

Johnetta Blakely, MD, MS, MMHC
Tennessee Oncology

Moshe Chasky, MD, FACP
Alliance Cancer Specialists

S. Fred Divers, MD
Genesis Cancer & Blood Institute & American Oncology Network, LLC.

Kathy Oubre, MS
Pontchartrain Cancer Center

Alti Rahman, MHA/MBA, CSSBB
American Oncology Network, LLC.

Emily Touloukian, DO
Coastal Cancer Center
Meet the 2025 COA Conference Keynote Speaker

Our powerful keynote speaker this year is Dr. David Fajgenbaum whose story is one of resilience, innovation, and a relentless drive to save lives—beginning with his own. Diagnosed with the rare and life-threatening Castleman disease while still in medical school, Dr. Fajgenbaum took matters into his own hands. He identified a repurposed drug that put him into remission, sparking his mission to match existing medications with rare diseases that lack treatments. Now in remission for a decade, he has expanded this work through Every Cure, a non-profit that uses AI to unlock the untapped potential of FDA-approved drugs to treat thousands of rare diseases….

Meet the 2025 COA Conference Keynote Speaker


Our powerful keynote speaker this year is Dr. David Fajgenbaum whose story is one of resilience, innovation, and a relentless drive to save lives—beginning with his own. Diagnosed with the rare and life-threatening Castleman disease while still in medical school, Dr. Fajgenbaum took matters into his own hands. He identified a repurposed drug that put him into remission, sparking his mission to match existing medications with rare diseases that lack treatments. Now in remission for a decade, he has expanded this work through Every Cure, a non-profit that uses AI to unlock the untapped potential of FDA-approved drugs to treat thousands of rare diseases.
Dr. Fajgenbaum’s groundbreaking work recently received over $48 million in federal funding to build a comprehensive drug-repurposing database, accelerating access to life-saving treatments for patients like Kaila Mabus, an 18-year-old Castleman survivor now in remission due to his efforts. His keynote promises to be both inspiring and actionable, offering a vision for transforming treatment through innovation and tenacity.
Thank you
To Our Exhibitors
Executive Platinum
AbbVie
At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
ADC Therapeutics
ADC Therapeutics is a leading, commercial-stage global pioneer in the field of antibody drug conjugates (ADCs).
Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors.
Our senior leaders are industry veterans with experience in both large pharmaceutical companies and biotechnology startups and our highly skilled global workforce is committed to transforming the lives of patients with cancer.
Agamon Health
Agamon Health is an innovative health-tech company focused on improving patient adherence to follow-up recommendations by automating the processes that enhance the effectiveness of cancer screening, incidental finding programs, and other early disease detection efforts. The Agamon Health Coordinate platform is an enterprise solution that can improve follow-up care across the entire patient care journey, from imaging surveillance to treatment to survivorship care. It automates manual follow-up processes to eliminate patient care gaps, improve organizational productivity, and create new downstream revenue streams. For additional information, visit agamonhealth.com
American Oncology Network
About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 290 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com.
American Regent
American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy.
American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.
Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.
Assertio Pharmaceuticals
We are a leading commercial pharmaceutical company bringing differentiated products to patients. We have a robust portfolio of branded prescription neurology, inflammation, pain, and oncology medications. The company has grown through business development including acquisitions, licensing, and mergers. We are looking to leverage our commercial excellence to be the partner of choice.
Association for Value-Based Care (AVBCC)
The mission of AVBCC is to provide a forum for payers, providers, and the entire oncology team to consider and evaluate the cost–value issues particular to cancer treatments and its impact on patient care and outcomes. This unique focus is achieved through discussions and collaborations with those involved in evaluating therapies, treating patients, and paying for care.
athenahealth
athenahealth strives to cure complexity and simplify the practice of healthcare. Our innovative technology includes electronic health records, revenue cycle management, and patient engagement solutions that help healthcare providers, administrators, and practices eliminate friction for patients while getting paid efficiently. We’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. Learn more at athenahealth.com
Caris Life Sciences
Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
Coherus Biosciences
Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of novel immunotherapies to treat cancer.
Eagle Pharmaceuticals
Florida Cancer Specialists & Research Institute
Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation* and has been recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award. Trained in prestigious medical schools and research institutes, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
*Prior to approval
Genentech
Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com.
Genomic Testing Cooperative
GTC offers genomic profiling of DNA, cfDNA, RNA and cfRNA for both solid and hematologic cancers to communities everywhere. We have a turn-around time of 5-10 days and a QNS rate of less than 1%. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC’s testing is NY state approved and covered by Medicare and most insurances. Our RNA sequencing capabilities go beyond just the detection of fusions and include alternative splicing, gene expression, exon skipping, and more.
Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Integrated Medical Systems, Inc.
IMS is a nationwide distributor specializing in the alternate site market since 1994. We offer a wide range of disposable products for infusion, oncology, respiratory, enteral feeding, and cleanroom needs, along with flexible biomedical services including equipment rental and purchase options from top manufacturers for exceptional patient care.
McKesson
NeoGenomics
NeoGenomics is a premier cancer diagnostics company, specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP accredited and CLIA certified laboratories for full-service sample processing and analysis services throughout the US; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom.
Oncentric
At Oncentric, our vision is to transform the way oncology care is delivered by making advanced, personalized, and efficient cancer treatment accessible to all. We believe that oncology practices of all sizes should have access to the same level of cutting-edge technology and comprehensive support that large healthcare systems enjoy. Whether you’re a small clinic serving a local community or a large cancer center treating patients from across the region, Oncentric is here to ensure that you have everything you need to provide the best possible care.
ONCOassist
ONCOassist is a free decision-support app for oncology professionals.
It is the only oncology app on the market with the required regulatory approval for use in hospital settings. With over 89,000 registered users globally, ONCOassist offers unique tools and content tailored specifically to oncology professionals.
OneOncology, LLC
OneOncology was founded by community oncologists, for community oncologists, with the mission of
improving the lives of everyone living with cancer. Our goal is to enable community oncology practices
to remain independent and to improve patient access to care in their communities, all at a lower cost
than in the hospital setting. OneOncology supports our platform of community oncology practices
through group purchasing, operational optimization, data analytics, practice growth, and clinical
innovation. Our 1,575 cancer care providers care for approximately 915,000 patients at more than 520
sites of care nationwide.
PharmaEssentia
PharmaEssentia Corporation, headquartered in Taiwan, with U.S. subsidiaries in Burlington and Bedford, MA, is a rapidly growing biopharmaceutical innovator. The company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea. Visit our website to learn more.
Qure4u
Qure4u is the award-winning, all-in-one digital solution that helps you win patients, automate workflows, and get paid faster. No other platform is as user-friendly for patients, providers, and staff. Patients can use any device without the need to log in. Providers and staff work inside their EHR, where one-click functionality makes tasks faster and more efficient.
We mean fast—register patients in less than 1 minute, with 50-60% of appointments self-scheduled by patients. Ninety percent of co-payments are collected pre-visit, and 95% of patients ROI quiz and find out.
The feedback speaks for itself—we received the most 5-star reviews on the athenahealth Marketplace for two years in a row, reflecting the value we bring to our customers.
- Easy-Access Tools: Self-scheduling, walk-in management, staff scheduling, and more.
- Scheduling Optimization: Tools like Booking Booster, which auto-fills canceled appointments.
- Automated Patient Arrival: Achieve 90% check-in from home, eliminate paper at the front desk, and enhance patient tracking and navigation.
- Communication Automation: Phone call automation with chatbot integration, secure text messaging, procedure care plans, and more.
- Robust Analytics: Analytics across the entire patient journey, enabling data-driven decision-making to enhance patient experiences and operational efficiency.
We’re reinventing what’s possible in healthcare, and we’re ready to start the conversation when you are.
Regeneron Pharmaceuticals
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development. Visit www.Regeneron.com to learn more.
RxVantage
RxVantage is transforming the way physicians and their practice teams make healthcare connections that elevate the practice of medicine. The only all-in-one provider-preferred engagement platform of its kind, RxVantage intelligently connects healthcare providers with resources, including the precise life sciences field experts, when they need them and in a manner that fits seamlessly into their workflow.
For more information, visit www.rxvantage.com.
Smirta Innovations
About Us:
Smirta Innovations is a leading provider of cutting-edge solutions tailored specifically for oncology practices. Our mission is to empower cancer care providers with tools that streamline operations, optimize workflows, and enhance patient care. By leveraging data-driven insights and advanced technology, we aim to improve the efficiency and effectiveness of oncology operations.
Our Flagship Product: OncoSmart®
OncoSmart® is an intelligent resource optimization platform designed to address common operational challenges faced by oncology practices. Currently implemented in over 80 centers, including infusion and radiology facilities, OncoSmart® has consistently delivered measurable results.
Key Features of OncoSmart®:
- iOptimize: Balances patient flow using real-time data to eliminate midday peaks and improve operational efficiency.
- iAssign: Automates nurse assignments based on patient acuity and staffing, ensuring balanced workloads and reducing burnout.
- iNtellisite: Provides actionable insights with data-driven KPIs, helping practices make informed decisions about staff, resources, and scheduling.
Benefits:
- Reduced staff burnout and improved nurse satisfaction.
- Enhanced patient flow and minimized delays.
- Maximized infusion room and resource utilization.
- Clear visibility into operational metrics for better decision-making.
Why Choose Smirta?
Smirta’s solutions are designed in collaboration with oncology professionals to meet the unique needs of cancer care providers. Our expertise, combined with a commitment to affordability and results, sets us apart from competitors. Whether you’re looking to address midday patient volume peaks, improve staff allocation, or streamline scheduling, OncoSmart® provides a proven path forward.
Stemline Therapeutics
Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics.
The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.
Unlimited Systems
Unlimited Systems provides a platform for a wide range of specialty healthcare practices seeking measurable increases in staff productivity, cash flow, and revenue with Unlimited Financials. Unlimited Financials is a full-featured revenue cycle platform with detailed analytics and task-driven workflows from start to finish. Specialty healthcare practices using Unlimited Financials can be confident that they will achieve peak financial performance.
Gold
AbbVie
At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
ADC Therapeutics
ADC Therapeutics is a leading, commercial-stage global pioneer in the field of antibody drug conjugates (ADCs).
Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors.
Our senior leaders are industry veterans with experience in both large pharmaceutical companies and biotechnology startups and our highly skilled global workforce is committed to transforming the lives of patients with cancer.
Agamon Health
Agamon Health is an innovative health-tech company focused on improving patient adherence to follow-up recommendations by automating the processes that enhance the effectiveness of cancer screening, incidental finding programs, and other early disease detection efforts. The Agamon Health Coordinate platform is an enterprise solution that can improve follow-up care across the entire patient care journey, from imaging surveillance to treatment to survivorship care. It automates manual follow-up processes to eliminate patient care gaps, improve organizational productivity, and create new downstream revenue streams. For additional information, visit agamonhealth.com
American Oncology Network
About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 290 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com.
American Regent
American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy.
American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.
Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.
Assertio Pharmaceuticals
We are a leading commercial pharmaceutical company bringing differentiated products to patients. We have a robust portfolio of branded prescription neurology, inflammation, pain, and oncology medications. The company has grown through business development including acquisitions, licensing, and mergers. We are looking to leverage our commercial excellence to be the partner of choice.
Association for Value-Based Care (AVBCC)
The mission of AVBCC is to provide a forum for payers, providers, and the entire oncology team to consider and evaluate the cost–value issues particular to cancer treatments and its impact on patient care and outcomes. This unique focus is achieved through discussions and collaborations with those involved in evaluating therapies, treating patients, and paying for care.
athenahealth
athenahealth strives to cure complexity and simplify the practice of healthcare. Our innovative technology includes electronic health records, revenue cycle management, and patient engagement solutions that help healthcare providers, administrators, and practices eliminate friction for patients while getting paid efficiently. We’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. Learn more at athenahealth.com
Caris Life Sciences
Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
Coherus Biosciences
Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of novel immunotherapies to treat cancer.
Eagle Pharmaceuticals
Florida Cancer Specialists & Research Institute
Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation* and has been recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award. Trained in prestigious medical schools and research institutes, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
*Prior to approval
Genentech
Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com.
Genomic Testing Cooperative
GTC offers genomic profiling of DNA, cfDNA, RNA and cfRNA for both solid and hematologic cancers to communities everywhere. We have a turn-around time of 5-10 days and a QNS rate of less than 1%. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC’s testing is NY state approved and covered by Medicare and most insurances. Our RNA sequencing capabilities go beyond just the detection of fusions and include alternative splicing, gene expression, exon skipping, and more.
Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Integrated Medical Systems, Inc.
IMS is a nationwide distributor specializing in the alternate site market since 1994. We offer a wide range of disposable products for infusion, oncology, respiratory, enteral feeding, and cleanroom needs, along with flexible biomedical services including equipment rental and purchase options from top manufacturers for exceptional patient care.
McKesson
NeoGenomics
NeoGenomics is a premier cancer diagnostics company, specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP accredited and CLIA certified laboratories for full-service sample processing and analysis services throughout the US; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom.
Oncentric
At Oncentric, our vision is to transform the way oncology care is delivered by making advanced, personalized, and efficient cancer treatment accessible to all. We believe that oncology practices of all sizes should have access to the same level of cutting-edge technology and comprehensive support that large healthcare systems enjoy. Whether you’re a small clinic serving a local community or a large cancer center treating patients from across the region, Oncentric is here to ensure that you have everything you need to provide the best possible care.
ONCOassist
ONCOassist is a free decision-support app for oncology professionals.
It is the only oncology app on the market with the required regulatory approval for use in hospital settings. With over 89,000 registered users globally, ONCOassist offers unique tools and content tailored specifically to oncology professionals.
OneOncology, LLC
OneOncology was founded by community oncologists, for community oncologists, with the mission of
improving the lives of everyone living with cancer. Our goal is to enable community oncology practices
to remain independent and to improve patient access to care in their communities, all at a lower cost
than in the hospital setting. OneOncology supports our platform of community oncology practices
through group purchasing, operational optimization, data analytics, practice growth, and clinical
innovation. Our 1,575 cancer care providers care for approximately 915,000 patients at more than 520
sites of care nationwide.
PharmaEssentia
PharmaEssentia Corporation, headquartered in Taiwan, with U.S. subsidiaries in Burlington and Bedford, MA, is a rapidly growing biopharmaceutical innovator. The company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea. Visit our website to learn more.
Qure4u
Qure4u is the award-winning, all-in-one digital solution that helps you win patients, automate workflows, and get paid faster. No other platform is as user-friendly for patients, providers, and staff. Patients can use any device without the need to log in. Providers and staff work inside their EHR, where one-click functionality makes tasks faster and more efficient.
We mean fast—register patients in less than 1 minute, with 50-60% of appointments self-scheduled by patients. Ninety percent of co-payments are collected pre-visit, and 95% of patients ROI quiz and find out.
The feedback speaks for itself—we received the most 5-star reviews on the athenahealth Marketplace for two years in a row, reflecting the value we bring to our customers.
- Easy-Access Tools: Self-scheduling, walk-in management, staff scheduling, and more.
- Scheduling Optimization: Tools like Booking Booster, which auto-fills canceled appointments.
- Automated Patient Arrival: Achieve 90% check-in from home, eliminate paper at the front desk, and enhance patient tracking and navigation.
- Communication Automation: Phone call automation with chatbot integration, secure text messaging, procedure care plans, and more.
- Robust Analytics: Analytics across the entire patient journey, enabling data-driven decision-making to enhance patient experiences and operational efficiency.
We’re reinventing what’s possible in healthcare, and we’re ready to start the conversation when you are.
Regeneron Pharmaceuticals
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development. Visit www.Regeneron.com to learn more.
RxVantage
RxVantage is transforming the way physicians and their practice teams make healthcare connections that elevate the practice of medicine. The only all-in-one provider-preferred engagement platform of its kind, RxVantage intelligently connects healthcare providers with resources, including the precise life sciences field experts, when they need them and in a manner that fits seamlessly into their workflow.
For more information, visit www.rxvantage.com.
Smirta Innovations
About Us:
Smirta Innovations is a leading provider of cutting-edge solutions tailored specifically for oncology practices. Our mission is to empower cancer care providers with tools that streamline operations, optimize workflows, and enhance patient care. By leveraging data-driven insights and advanced technology, we aim to improve the efficiency and effectiveness of oncology operations.
Our Flagship Product: OncoSmart®
OncoSmart® is an intelligent resource optimization platform designed to address common operational challenges faced by oncology practices. Currently implemented in over 80 centers, including infusion and radiology facilities, OncoSmart® has consistently delivered measurable results.
Key Features of OncoSmart®:
- iOptimize: Balances patient flow using real-time data to eliminate midday peaks and improve operational efficiency.
- iAssign: Automates nurse assignments based on patient acuity and staffing, ensuring balanced workloads and reducing burnout.
- iNtellisite: Provides actionable insights with data-driven KPIs, helping practices make informed decisions about staff, resources, and scheduling.
Benefits:
- Reduced staff burnout and improved nurse satisfaction.
- Enhanced patient flow and minimized delays.
- Maximized infusion room and resource utilization.
- Clear visibility into operational metrics for better decision-making.
Why Choose Smirta?
Smirta’s solutions are designed in collaboration with oncology professionals to meet the unique needs of cancer care providers. Our expertise, combined with a commitment to affordability and results, sets us apart from competitors. Whether you’re looking to address midday patient volume peaks, improve staff allocation, or streamline scheduling, OncoSmart® provides a proven path forward.
Stemline Therapeutics
Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics.
The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.
Unlimited Systems
Unlimited Systems provides a platform for a wide range of specialty healthcare practices seeking measurable increases in staff productivity, cash flow, and revenue with Unlimited Financials. Unlimited Financials is a full-featured revenue cycle platform with detailed analytics and task-driven workflows from start to finish. Specialty healthcare practices using Unlimited Financials can be confident that they will achieve peak financial performance.
Silver
AbbVie
At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
ADC Therapeutics
ADC Therapeutics is a leading, commercial-stage global pioneer in the field of antibody drug conjugates (ADCs).
Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors.
Our senior leaders are industry veterans with experience in both large pharmaceutical companies and biotechnology startups and our highly skilled global workforce is committed to transforming the lives of patients with cancer.
Agamon Health
Agamon Health is an innovative health-tech company focused on improving patient adherence to follow-up recommendations by automating the processes that enhance the effectiveness of cancer screening, incidental finding programs, and other early disease detection efforts. The Agamon Health Coordinate platform is an enterprise solution that can improve follow-up care across the entire patient care journey, from imaging surveillance to treatment to survivorship care. It automates manual follow-up processes to eliminate patient care gaps, improve organizational productivity, and create new downstream revenue streams. For additional information, visit agamonhealth.com
American Oncology Network
About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 290 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com.
American Regent
American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy.
American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.
Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.
Assertio Pharmaceuticals
We are a leading commercial pharmaceutical company bringing differentiated products to patients. We have a robust portfolio of branded prescription neurology, inflammation, pain, and oncology medications. The company has grown through business development including acquisitions, licensing, and mergers. We are looking to leverage our commercial excellence to be the partner of choice.
Association for Value-Based Care (AVBCC)
The mission of AVBCC is to provide a forum for payers, providers, and the entire oncology team to consider and evaluate the cost–value issues particular to cancer treatments and its impact on patient care and outcomes. This unique focus is achieved through discussions and collaborations with those involved in evaluating therapies, treating patients, and paying for care.
athenahealth
athenahealth strives to cure complexity and simplify the practice of healthcare. Our innovative technology includes electronic health records, revenue cycle management, and patient engagement solutions that help healthcare providers, administrators, and practices eliminate friction for patients while getting paid efficiently. We’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. Learn more at athenahealth.com
Caris Life Sciences
Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
Coherus Biosciences
Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of novel immunotherapies to treat cancer.
Eagle Pharmaceuticals
Florida Cancer Specialists & Research Institute
Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation* and has been recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award. Trained in prestigious medical schools and research institutes, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
*Prior to approval
Genentech
Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com.
Genomic Testing Cooperative
GTC offers genomic profiling of DNA, cfDNA, RNA and cfRNA for both solid and hematologic cancers to communities everywhere. We have a turn-around time of 5-10 days and a QNS rate of less than 1%. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC’s testing is NY state approved and covered by Medicare and most insurances. Our RNA sequencing capabilities go beyond just the detection of fusions and include alternative splicing, gene expression, exon skipping, and more.
Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Integrated Medical Systems, Inc.
IMS is a nationwide distributor specializing in the alternate site market since 1994. We offer a wide range of disposable products for infusion, oncology, respiratory, enteral feeding, and cleanroom needs, along with flexible biomedical services including equipment rental and purchase options from top manufacturers for exceptional patient care.
McKesson
NeoGenomics
NeoGenomics is a premier cancer diagnostics company, specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP accredited and CLIA certified laboratories for full-service sample processing and analysis services throughout the US; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom.
Oncentric
At Oncentric, our vision is to transform the way oncology care is delivered by making advanced, personalized, and efficient cancer treatment accessible to all. We believe that oncology practices of all sizes should have access to the same level of cutting-edge technology and comprehensive support that large healthcare systems enjoy. Whether you’re a small clinic serving a local community or a large cancer center treating patients from across the region, Oncentric is here to ensure that you have everything you need to provide the best possible care.
ONCOassist
ONCOassist is a free decision-support app for oncology professionals.
It is the only oncology app on the market with the required regulatory approval for use in hospital settings. With over 89,000 registered users globally, ONCOassist offers unique tools and content tailored specifically to oncology professionals.
OneOncology, LLC
OneOncology was founded by community oncologists, for community oncologists, with the mission of
improving the lives of everyone living with cancer. Our goal is to enable community oncology practices
to remain independent and to improve patient access to care in their communities, all at a lower cost
than in the hospital setting. OneOncology supports our platform of community oncology practices
through group purchasing, operational optimization, data analytics, practice growth, and clinical
innovation. Our 1,575 cancer care providers care for approximately 915,000 patients at more than 520
sites of care nationwide.
PharmaEssentia
PharmaEssentia Corporation, headquartered in Taiwan, with U.S. subsidiaries in Burlington and Bedford, MA, is a rapidly growing biopharmaceutical innovator. The company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea. Visit our website to learn more.
Qure4u
Qure4u is the award-winning, all-in-one digital solution that helps you win patients, automate workflows, and get paid faster. No other platform is as user-friendly for patients, providers, and staff. Patients can use any device without the need to log in. Providers and staff work inside their EHR, where one-click functionality makes tasks faster and more efficient.
We mean fast—register patients in less than 1 minute, with 50-60% of appointments self-scheduled by patients. Ninety percent of co-payments are collected pre-visit, and 95% of patients ROI quiz and find out.
The feedback speaks for itself—we received the most 5-star reviews on the athenahealth Marketplace for two years in a row, reflecting the value we bring to our customers.
- Easy-Access Tools: Self-scheduling, walk-in management, staff scheduling, and more.
- Scheduling Optimization: Tools like Booking Booster, which auto-fills canceled appointments.
- Automated Patient Arrival: Achieve 90% check-in from home, eliminate paper at the front desk, and enhance patient tracking and navigation.
- Communication Automation: Phone call automation with chatbot integration, secure text messaging, procedure care plans, and more.
- Robust Analytics: Analytics across the entire patient journey, enabling data-driven decision-making to enhance patient experiences and operational efficiency.
We’re reinventing what’s possible in healthcare, and we’re ready to start the conversation when you are.
Regeneron Pharmaceuticals
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development. Visit www.Regeneron.com to learn more.
RxVantage
RxVantage is transforming the way physicians and their practice teams make healthcare connections that elevate the practice of medicine. The only all-in-one provider-preferred engagement platform of its kind, RxVantage intelligently connects healthcare providers with resources, including the precise life sciences field experts, when they need them and in a manner that fits seamlessly into their workflow.
For more information, visit www.rxvantage.com.
Smirta Innovations
About Us:
Smirta Innovations is a leading provider of cutting-edge solutions tailored specifically for oncology practices. Our mission is to empower cancer care providers with tools that streamline operations, optimize workflows, and enhance patient care. By leveraging data-driven insights and advanced technology, we aim to improve the efficiency and effectiveness of oncology operations.
Our Flagship Product: OncoSmart®
OncoSmart® is an intelligent resource optimization platform designed to address common operational challenges faced by oncology practices. Currently implemented in over 80 centers, including infusion and radiology facilities, OncoSmart® has consistently delivered measurable results.
Key Features of OncoSmart®:
- iOptimize: Balances patient flow using real-time data to eliminate midday peaks and improve operational efficiency.
- iAssign: Automates nurse assignments based on patient acuity and staffing, ensuring balanced workloads and reducing burnout.
- iNtellisite: Provides actionable insights with data-driven KPIs, helping practices make informed decisions about staff, resources, and scheduling.
Benefits:
- Reduced staff burnout and improved nurse satisfaction.
- Enhanced patient flow and minimized delays.
- Maximized infusion room and resource utilization.
- Clear visibility into operational metrics for better decision-making.
Why Choose Smirta?
Smirta’s solutions are designed in collaboration with oncology professionals to meet the unique needs of cancer care providers. Our expertise, combined with a commitment to affordability and results, sets us apart from competitors. Whether you’re looking to address midday patient volume peaks, improve staff allocation, or streamline scheduling, OncoSmart® provides a proven path forward.
Stemline Therapeutics
Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics.
The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.
Unlimited Systems
Unlimited Systems provides a platform for a wide range of specialty healthcare practices seeking measurable increases in staff productivity, cash flow, and revenue with Unlimited Financials. Unlimited Financials is a full-featured revenue cycle platform with detailed analytics and task-driven workflows from start to finish. Specialty healthcare practices using Unlimited Financials can be confident that they will achieve peak financial performance.
Get Updates on the 2025 Community Oncology Conference
Want to receive Conference updates directly in your inbox? Sign up here!